<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="66462">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02240654</url>
  </required_header>
  <id_info>
    <org_study_id>1160.144</org_study_id>
    <nct_id>NCT02240654</nct_id>
  </id_info>
  <brief_title>Evaluation of Potential Off-label Use of Dabigatran Etexilate in Europe</brief_title>
  <official_title>Evaluation of Potential Off-label Use of Dabigatran Etexilate in Europe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This is a descriptive, observational, multi-country European cross-sectional study of new
      users of dabigatran etexilate that aims to characterise on- and off-label status and other
      medical characteristics at the time of the first captured prescription of dabigatran
      etexilate in each database. The study will be conducted using Cegedim Strategic Database
      (CSD, France), Danish National Databases (Denmark) and Clinical Practice Research Datalink
      (CPRD, UK).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characteristics of new users of dabigatran etexilate</measure>
    <time_frame>Prior to and at the time of dabigatran etexilate initiation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of off-label use</measure>
    <time_frame>From launch of dabigatran etexilate in each country until the target number of new users is reached in each database</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Dabigatran etexilate</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        New users of dabigatran etexilate in each database
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Have at least 1 year of enrolment in the electronic database.

          2. Have not been prescribed dabigatran etexilate during the 1-year period prior to the
             index date.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1160.144.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 27, 2016</lastchanged_date>
  <firstreceived_date>September 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
